<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833233</url>
  </required_header>
  <id_info>
    <org_study_id>16-495</org_study_id>
    <nct_id>NCT02833233</nct_id>
  </id_info>
  <brief_title>A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer</brief_title>
  <official_title>A Pilot Study of Pre-Operative, Single-Dose Ipilimumab, Nivolumab and Cryoablation in Early Stage/Resectable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the safety of combining two strategies called&#xD;
      &quot;cryoablation&quot; and &quot;immune therapy&quot; in women with curable early stage breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>12 weeks after ipilimumab/nivolumab administration.</time_frame>
    <description>Safety will be evaluated for all treated subjects using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v4.0 (CTCAE).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cryoablation and Immune Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo breast biopsy with cryoablation 7-10 days prior to the planned surgery, and ipilimumab with nivolumab administration 1-5 days before cryoablation. All patients will undergo surgery at the pre-determined day defined at the initial surgical consultation. Women will receive ipilimumab and nivolumab 1-5 days prior to US or MRI-guided core biopsy and cryoablation date. Intravenous ipilimumab will be administered as a single 1 mg/kg dose to be infused intravenously over 90 minutes. Intravenous nivolumab will be administered as a single 3 mg/kg dose to be infused intravenously over 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <arm_group_label>Cryoablation and Immune Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Cryoablation and Immune Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Cryoablation and Immune Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women age 18 years or older&#xD;
&#xD;
          -  Confirmed histologic diagnosis of invasive adenocarcinoma of the breast, including&#xD;
             MSKCC pathology confirmation&#xD;
&#xD;
          -  ER, PR and HER2 testing in progress (i.e. on outside or MSKCC biopsy report)&#xD;
&#xD;
               -  HER2-positive pathology is permitted&#xD;
&#xD;
          -  Operable tumor measuring ≥1.5 cm in maximal diameter&#xD;
&#xD;
               -  Any nodal status&#xD;
&#xD;
               -  Multifocal and multicentric disease is permitted&#xD;
&#xD;
               -  Synchronous bilateral invasive breast cancer is permitted&#xD;
&#xD;
               -  The tumor should be more than 5 mm from the skin&#xD;
&#xD;
          -  No indication of distant metastases&#xD;
&#xD;
          -  Breast surgery planned&#xD;
&#xD;
          -  Tumor amenable to cryoablation as determined by radiologist&#xD;
&#xD;
          -  ECOG performance status score of 0 or 1&#xD;
&#xD;
          -  Screening laboratory values must meet the following criteria:&#xD;
&#xD;
               -  White blood cells (WBCs) ≥ 2000/μL&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1500/μL&#xD;
&#xD;
               -  Platelets ≥ 100 x 10^3/μL&#xD;
&#xD;
               -  Hemoglobin ≥ 11.0 g/dL&#xD;
&#xD;
               -  Serum creatinine ≤ 2 mg/dL (or glomerular filtration rate ≥ 40 ml/min)&#xD;
&#xD;
               -  AST ≤ 2.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  ALT ≤ 2.5 x ULN&#xD;
&#xD;
               -  Bilirubin within normal limits (except subjects with Gilbert's syndrome, who must&#xD;
                  have total bilirubin &lt; 3.0 mg/dL)&#xD;
&#xD;
               -  Negative HIV screening test&#xD;
&#xD;
               -  Negative screening tests for Hepatitis B and Hepatitis C. Patients with positive&#xD;
                  results that do not indicate true active or chronic infection may enroll after&#xD;
                  discussion and consensus agreement by the treating physician and principal&#xD;
                  investigator.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must be using an acceptable method of&#xD;
             contraception to avoid pregnancy throughout the study and for at least 3 months after&#xD;
             the last dose of ipilimumab in such a manner that the risk of pregnancy is minimized.&#xD;
             See below for the definition of WOCBP.&#xD;
&#xD;
          -  WOCBP must have a negative serum pregnancy test within 14 days prior to the first dose&#xD;
             of ipilimumab/nivolumab&#xD;
&#xD;
          -  Women must not be breastfeeding&#xD;
&#xD;
          -  Willing to adhere to the study visit schedule and the prohibitions and restrictions&#xD;
             specified in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
          -  Medical history and concurrent diseases&#xD;
&#xD;
               -  Subjects with active, known or suspected autoimmune disease. Subjects with&#xD;
                  vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune&#xD;
                  condition only requiring hormone replacement, psoriasis not requiring systemic&#xD;
                  treatment, or conditions not expected to recur in the absence of an external&#xD;
                  trigger are permitted to enroll.&#xD;
&#xD;
               -  Any serious or uncontrolled medical disorder that, in the opinion of the&#xD;
                  investigator, may increase the risk associated with study participation or study&#xD;
                  drug administration, impair the ability of the subject to receive protocol&#xD;
                  therapy, or interfere with the interpretation of study results.&#xD;
&#xD;
          -  Prohibited Treatments and/or Therapies&#xD;
&#xD;
               -  Chronic use of immunosuppressants and/or systemic corticosteroids (used in the&#xD;
                  management of cancer or non-cancer-related illnesses). However, use of&#xD;
                  corticosteroids is allowed for the treatment of immune related Adverse Events&#xD;
                  (irAEs), or adrenal insufficiency.&#xD;
&#xD;
               -  Any non-oncology vaccine therapy used for prevention of infectious diseases&#xD;
                  within 4 weeks prior to first dose of ipilimumab.&#xD;
&#xD;
               -  Prior treatment with a CD137 agonist, ipilimumab or other CTLA4 inhibitor;&#xD;
&#xD;
               -  Prior investigational agents within 2 weeks prior to first dose of ipilimumab;&#xD;
&#xD;
               -  Prior therapy with any anti-cancer agents including chemotherapy, adjuvant&#xD;
                  chemotherapy, immunosuppressive agents, surgery or radiotherapy within 2 weeks&#xD;
                  prior to first dose of ipilimumab.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Comen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early stage</keyword>
  <keyword>Resectable</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Cryoablation</keyword>
  <keyword>16-495</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

